Dymista Allergy Nasal Spray

Dymista is a medical nasal spray used for the treatment of moderate to severe allergic rhinitis and hayfever. Originally developed by the German pharmaceutical company Meda AB, it combines two active ingredients: azelastine hydrochloride and fluticasone propionate to provide both antihistamine and anti-inflammatory relief. The brand has a strong presence in the Australian market as a pharmacy-only medicine. Manufacturing for this product occurs in multiple locations across Europe and North America to serve global markets.

The brand's ownership transitioned as part of significant pharmaceutical industry consolidation. Meda AB was acquired by the American company Mylan in 2016. Subsequently, Mylan merged with Pfizer's Upjohn division in 2020 to form Viatris, a global healthcare corporation. Today, Viatris remains the ultimate owner of the Dymista brand, managing its global distribution and regulatory compliance. In Australia, the product is distributed by Viatris Pty Ltd, which ensures the product meets local Therapeutic Goods Administration (TGA) standards.